Los frmacos antihiperglucemiantes disponibles hasta hace poco mejoraban el control glucmico, pero sin beneficios sobre el riesgo cardiovascular y/o renal
The plasma concentration data for rats, minipigs and NHPs, were received in Excel format and imported into Phoenix WinNonlin version 8.1 (Certara L.P., Princeton, NJ, USA) for PK evaluation
Targets fat not muscle*: Morosil has been shown to reduce waist and hip circumference and support healthy body composition when paired with a balanced diet and exercise.
The Endocrine Society's 2023 obesity pharmacotherapy guideline states: "When a patient does not achieve adequate weight loss on a maximally tolerated dose of a GLP-1 receptor agonist, switching to an agent with a broader receptor profile is a reasonable escalation strategy, provided the patient is counseled on the investigational status of newer agents" [5]
The Science Triple-Agonist Technology Retatrutide simultaneously activates three metabolic receptor pathways: GLP-1, GIP, and glucagon
Possible effects include nausea, reflux, constipation, or fatigue all of which are monitored closely and managed conservatively
